What exclusivity did Dr. Reddy’s (or DRL) have for fluoxetine/Prozac, and when did it end?
I can’t answer this accurately from the provided information. Your question combines three items—“Dr. Reddy’s,” “fluoxetine,” and “Prozac,” plus “exclusivity 2001 revenue”—but no details are given about which specific product, market (U.S. or another country), regulatory exclusivity type (patent vs. Hatch-Waxman 180-day exclusivity vs. marketing exclusivity), or which “2001 revenue” figure you mean.
How to get the right “2001 revenue” number for fluoxetine/Prozac (what to look for)
To match what you’re asking, you’d typically need a source that states both:
- the relevant exclusivity period for the specific brand or generic pathway (for example, whether a 180-day exclusivity shipment period applied), and
- the revenue figure for 2001 for the company/product you care about (brand Prozac revenue, or DRL’s revenue from fluoxetine).
Common places these numbers appear are annual reports (segment/product revenue), investor decks, or filings that cite historical sales.
If you meant generic entry timing: how exclusivity can affect 2001 revenue
If the “exclusivity” in your question refers to branded Prozac protection preventing generic competition, the key driver of revenue around 2001 would be when generics entered and whether multiple ANDA filers launched concurrently. Without the exact drug/listing and geography, the entry timing (and resulting revenue impact) can’t be determined.
Quick clarification so I can compute/locate the exact answer
Reply with any two of the following, and I’ll produce the most precise answer possible:
1) Country: U.S. (FDA/ANDA) or another market?
2) Which revenue: Prozac brand revenue in 2001, or Dr. Reddy’s fluoxetine revenue in 2001?
3) Which exclusivity: patent expiry date, FDA “180-day exclusivity,” or “marketing exclusivity”?
4) If you have it, the exact product label (strength/form) and any link or document name you’re using.
Sources: none (no provided source content to cite).